A solution to achieve sequencing from SARS-CoV-2 specimens with low viral loads: concatenation of reads from independent reactions
-
Published:2024-05-30
Issue:1
Volume:21
Page:
-
ISSN:1743-422X
-
Container-title:Virology Journal
-
language:en
-
Short-container-title:Virol J
Author:
Cerro-Monje Alba, Buenestado-Serrano SergioORCID, Palomino-Cabrera Rosalía, Molero-Salinas Andrea, Herranz Marta, Alonso Roberto, Catalán Pilar, Muñoz Patricia, García de Viedma Darío, Pérez-Lago Laura,
Abstract
Abstract
Background
During the pandemic, whole genome sequencing was critical to characterize SARS-CoV-2 for surveillance, clinical and therapeutical purposes. However, low viral loads in specimens often led to suboptimal sequencing, making lineage assignment and phylogenetic analysis difficult. We propose an alternative approach to sequencing these specimens that involves sequencing in triplicate and concatenation of the reads obtained using bioinformatics. This proposal is based on the hypothesis that the uncovered regions in each replicate differ and that concatenation would compensate for these gaps and recover a larger percentage of the sequenced genome.
Results
Whole genome sequencing was performed in triplicate on 30 samples with Ct > 32 and the benefit of replicate read concatenation was assessed. After concatenation: i) 28% of samples reached the standard quality coverage threshold (> 90% genome covered > 30x); ii) 39% of samples did not reach the coverage quality thresholds but coverage improved by more than 40%; and iii) SARS-CoV-2 lineage assignment was possible in 68.7% of samples where it had been impaired.
Conclusions
Concatenation of reads from replicate sequencing reactions provides a simple way to access hidden information in the large proportion of SARS-CoV-2-positive specimens eliminated from analysis in standard sequencing schemes. This approach will enhance our potential to rule out involvement in outbreaks, to characterize reinfections and to identify lineages of concern for surveillance or therapeutical purposes.
Funder
Instituto de Salud Carlos III European Regional Development Fund Instituto de Investigación Sanitaria Gregorio Marañón
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ 2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–9. 3. Lambisia AW, Mohammed KS, Makori TO, Ndwiga L, Mburu MW, Morobe JM, Moraa EO, Musyoki J, Murunga N, Mwangi JN, Nokes DJ, Agoti CN, Ochola-Oyier LI, Githinji G. 2022. Optimization of the SARS-CoV-2 ARTIC Network V4 primers and whole genome sequencing protocol. Front Med 9. 4. Tao K, Tzou PL, Nouhin J, Bonilla H, Jagannathan P, Shafer RW. 2021. SARS-CoV-2 antiviral therapy. Clin Microbiol Rev 34. 5. Farinholt T, Doddapaneni H, Qin X, Menon V, Meng Q, Metcalf G, Chao H, Gingras MC, Avadhanula V, Farinholt P, Agrawal C, Muzny DM, Piedra PA, Gibbs RA, Petrosino J. 2021. Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections. BMC Med 19.
|
|